Share Email Print

Proceedings Paper

Optical biopsy of the prostate: can we TRUST (trans-rectal ultrasound-coupled spectral tomography)?
Author(s): Daqing Piao; Zhen Jiang; Kenneth E. Bartels; G. Reed Holyoak; Jerry W. Ritchey; Kendra Rock; Charlotte L. Ownby; Charles F. Bunting; Gennady Slobodov
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

Needle-based core-biopsy to locate prostate cancer relies heavily upon trans-rectal ultrasound (TRUS) imaging guidance. Ultrasonographic findings of classic hypoechoic peripheral zone lesions have a low specificity of ~28%, a low positive predictive value of ~29%, and an overall accuracy of ~43%, in prostate cancer diagnosis. The prevalence of isoechoic or nearly invisible prostate cancers on ultrasonography ranges from 25 to 42%. As a result, TRUS is useful and convenient to direct the needle trajectory following a systematic biopsy sampling template rather than to target only the potentially malignant lesion for focal-biopsy. To address this deficiency in the first-line of prostate cancer imaging, a trans-rectal ultrasound-coupled spectral tomography (TRUST) approach is being developed to non-invasively resolve the likely optical signatures of prostate malignancy. The approach has evolved from using one NIR wavelength to two NIR bands, and recently to three bands of NIR spectrum information. The concept has been evaluated on one normal canine prostate and three dogs with implanted prostate tumor developed as a model. The initial results implementing TRUST on the canine prostate tumor model includes: (1) quantifying substantially increased total hemoglobin concentration over the time-course of imaging in a rapidly growing prostate tumor; (2) confirming hypoxia in a prostatic cystic lesion; and (3) imaging hypoxic changes of a necrotic prostate tumor. Despite these interesting results, intensive technologic development is necessary for translating the approach to benefiting clinical practice, wherein the ultimate utility is not possibly to eliminate needle-biopsy but to perform focal-biopsy that is only necessary to confirm the cancer, as well as to monitor and predict treatment responses.

Paper Details

Date Published: 16 February 2011
PDF: 14 pages
Proc. SPIE 7895, Optical Biopsy IX, 78950I (16 February 2011); doi: 10.1117/12.876527
Show Author Affiliations
Daqing Piao, Oklahoma State Univ. (United States)
Zhen Jiang, Oklahoma State Univ. (United States)
Washington Univ. in St. Louis (United States)
Kenneth E. Bartels, Oklahoma State Univ. (United States)
G. Reed Holyoak, Oklahoma State Univ. (United States)
Jerry W. Ritchey, Oklahoma State Univ. (United States)
Kendra Rock, Oklahoma State Univ. (United States)
Charlotte L. Ownby, Oklahoma State Univ. (United States)
Charles F. Bunting, Oklahoma State Univ. (United States)
Gennady Slobodov, The Univ. of Oklahoma Health Sciences Ctr. (United States)

Published in SPIE Proceedings Vol. 7895:
Optical Biopsy IX
Robert R. Alfano, Editor(s)

© SPIE. Terms of Use
Back to Top